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SUMMARY 51 
The gut microbiome is critical in providing resistance against colonization by 52 
exogenous microorganisms. The mechanisms via which the gut microbiota provides 53 
colonization resistance (CR) have not been fully elucidated, but include secretion of 54 
antimicrobial products, nutrient competition, support of gut barrier integrity and 55 
bacteriophage deployment. However, bacterial enteric infections are an important 56 
cause of disease globally, indicating that microbiota-mediated CR can be disturbed, 57 
and become ineffective. Changes in microbiota composition, and potential 58 
subsequent disruption of CR, can be caused by various drugs, such as antibiotics, 59 
proton pump inhibitors, antidiabetics and antipsychotics, thereby providing 60 
opportunities for exogenous pathogens to colonize the gut and ultimately cause 61 
infection. In addition, the most prevalent bacterial enteropathogens, including 62 
Clostridioides difficile, Salmonella enterica serovar Typhimurium, enterohemorrhagic 63 
Escherichia coli, Shigella flexneri, Campylobacter jejuni, Vibrio cholerae, Yersinia 64 
enterocolitica and Listeria monocytogenes, can employ a wide array of mechanisms 65 
to overcome colonization resistance. This review aims to summarize current 66 
knowledge on how the gut microbiota can mediate colonization resistance against 67 
bacterial enteric infection, and on how bacterial enteropathogens can overcome this 68 
resistance.  69 
KEYWORDS colonization resistance, bacterial enteric infection, enteric pathogens, 70 
gut microbiota, microbiome, nutrient competition, mucus layer, bile acids, 71 
bacteriocins, short-chain fatty acids, bacteriophages, proton-pump inhibitors, 72 
metformin, antipsychotics  73 
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INTRODUCTION 74 
The human gastrointestinal tract is colonized by an enormous number of microbes, 75 
collectively termed gut microbiota, including bacteria, viruses, fungi, archaea and 76 
protozoa. Bacteria achieve the highest cell density, estimated to be approximately 77 
1011 bacteria/ml in the colon (1). Research has long focused on pathogenicity of 78 
microbes and not on their potential beneficial roles for human health. Beneficial roles 79 
include aiding in immune system maturation, production of short-chain fatty acids 80 
(SCFAs), vitamin synthesis and providing a barrier against colonization with potential 81 
pathogens (2). Additionally, the gut microbiota has extensive interactions with our 82 
immune system and it has been associated with many immune-mediated diseases 83 
both in and outside of the gut (3-5). Over the last ten years, there has been an 84 
increased interest in elucidating the bidirectional relationship between gut microbiota 85 
and human health and disease. This has been partly propelled by improved 86 
sequencing technologies, allowing the profiling of entire microbial communities at 87 
high efficiency and low costs (6).  88 
Hundreds of different bacterial species inhabiting the healthy human gut have been 89 
identified (7, 8). Initial studies seeking to elucidate the relationship between human 90 
microbiota and health and disease were largely observational; gut microbiota 91 
composition would be compared between diseased and healthy groups and 92 
subsequently associated with clinical markers (9). Currently, the field is moving 93 
towards more functional and mechanistic studies by including other –omics 94 
techniques.  95 
In healthy individuals, the gut microbiota provides protection against infection by 96 
deploying multiple mechanisms including secretion of antimicrobial products, nutrient 97 
competition, support of epithelial barrier integrity, bacteriophage deployment, and 98 
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immune activation. Together, these mechanisms contribute to resistance against 99 
colonization of exogenous microorganisms (colonization resistance, CR) (10). 100 
However, also in absence of a fully functional immune system, the gut microbiota 101 
can provide a crucial and nonredundant protection against a potentially lethal 102 
pathogen (11). This review will discuss the mechanisms used by gut microbiota to 103 
provide CR, the impact of various drugs on gut microbiota and thereby CR, and the 104 
strategies of specific bacterial pathogens to overcome CR and ultimately cause 105 
enteric infection. 106 
 107 
MECHANISMS PROVIDING COLONIZATION RESISTANCE 108 
The gut microbiota produces various products with antimicrobial effects, including 109 
SCFAs, secondary bile acids and bacteriocins. Each of these contribute to CR in a 110 
product-specific manner. The following section describes their general mechanisms 111 
of action. The contribution of the immune system in conferring CR has been 112 
extensively reviewed elsewhere and is outside the scope of this review (12, 13). 113 
 114 
Short-chain fatty acids  115 
SCFAs are mainly produced by bacteria through fermentation of non-digestible 116 
carbohydrates (Fig. 1) (14). The three main SCFAs are acetate, propionate and 117 
butyrate, constituting 90-95% of the total SCFA pool (15). During homeostatic 118 
conditions, butyrate is the main nutrient for enterocytes and is metabolized through 119 
β-oxidation. Hereby, an anaerobic milieu inside the gut can be maintained (16). 120 
SCFAs can impair bacterial growth by affecting intracellular pH and metabolic 121 
functioning. SCFA concentrations have been shown to inversely relate to pH 122 
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throughout different regions of the gut (17). At lower pH, SCFAs are more prevalent 123 
in their non-ionized form and these non-ionized acids can diffuse across the bacterial 124 
membrane into the cytoplasm. Within the cytoplasm they will dissociate, resulting in 125 
a build-up of anions and protons leading to a lower intracellular pH (18).  126 
In presence of acetate, metabolic functioning of Escherichia coli could be impaired 127 
by preventing biosynthesis of methionine, leading to accumulation of toxic 128 
homocysteine and growth inhibition. Growth inhibition was partly relieved by 129 
supplementing the growth medium with methionine, showing that this metabolic 130 
dysfunction is one of the factors by which SCFAs impair bacterial growth (19).  131 
 132 
Bile acids  133 
Bile acids, possessing antimicrobial properties, are produced by the liver and 134 
excreted in the intestinal tract to aid in the digestion of dietary lipids. After production 135 
of primary bile acids in the liver, they are subsequently conjugated with glycine or 136 
taurine, to increase solubility (20). These are then stored in the gallbladder, and 137 
upon food intake, are released into the duodenum to increase solubilization of 138 
ingested lipids. A large part of conjugated primary bile acids is reabsorbed in the 139 
distal ileum (50-90%), while the remainder can be subjected to bacterial metabolism 140 
in the colon (20). Here, conjugated bile acids can be deconjugated by bile salt 141 
hydrolases (BSH), which are abundantly present in the gut microbiome (21). 142 
Deconjugated primary bile acids can subsequently be converted into the two main 143 
secondary bile acids, deoxycholic acid and lithocholic acid, by few bacteria, mostly 144 
Clostridium species, via 7α-dehydroxylation through a complex biochemical pathway 145 
(21-23) (Fig. 1). A crucial step during the conversion is encoded by the baiCD gene, 146 
which is found in several Clostridium strains, including Clostridium scindens (24). 147 
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Deoxycholic acid is bactericidal to many bacteria, including Staphylococcus aureus, 148 
Bacteroides thetaiotaomicron, Clostridioides difficile, bifidobacteria and lactobacilli by 149 
membrane disruption and subsequent leakage of cellular content (25-28).  150 
The importance of bacteria for conversion of primary bile acids was demonstrated by 151 
investigating bile acid profiles in germ-free mice, where no secondary bile acids 152 
could be measured (29). Very few colonic bacteria, less than 0.025% of total gut 153 
microbiota, are capable of performing 7α-dehydroxylation (23, 30). One of these 154 
bacteria, C. scindens, is associated with colonization resistance against C. difficile 155 
through secondary bile acid production (22, 31). A follow-up in vivo study 156 
demonstrated that C. scindens provided CR in the first day post infection (p.i), but 157 
protection and secondary bile acid production was lost at 72 p.i (32). C. scindens on 158 
its own was also not sufficient to inhibit C. difficile outgrowth in humans (33). 159 
Together, these studies suggest that C. scindens either requires cooperation with 160 
other secondary-bile acid producing bacteria or that other mechanisms were 161 
involved in providing CR. The secondary bile acid lithocholic acid may exert its 162 
antimicrobial effects, and potentially its effects on CR, in an indirect manner. 163 
Lithocholic acid has been shown to enhance transcription for the antimicrobial 164 
peptide LL-37, in gut epithelium using a HT-29 cell line (34). However, no increased 165 
mRNA transcription nor protein translation of LL-37 was observed in another study 166 
using a Caco2 cell line (35).  167 
 168 
Bacteriocins 169 
Bacteriocins are short, toxic peptides produced by specific bacterial species that can 170 
inhibit colonization and growth of other species (36) (Fig. 1). Their mechanisms of 171 
action are multifold and include disturbing RNA and DNA metabolism, and killing 172 
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cells through pore formation in the cell membrane (37-40). Bacteriocins can be 173 
divided into those produced by Gram-positive bacteria, and those produced by 174 
Gram-negative bacteria. Further classification of bacteriocins has been extensively 175 
discussed elsewhere,  (41, 42). Bacteriocins produced by Gram-positive bacteria are 176 
mostly produced by lactic acid bacteria (e.g. Lactococcus and Lactobacillus) and 177 
some Streptococcus species, and are further subdivided into three major classes on 178 
the basis of the molecular weight of the bacteriocins and the presence of post-179 
translational modifications (42). Bacteriocins produced by Gram-negative bacteria, 180 
mostly by Enterobacteriaceae, can be broadly divided into high molecular weight 181 
proteins (colicins) and lower molecular weight peptides (microcins) (41). 182 
The lantibiotic nisin is the best studied bacteriocin and is produced by Lactococcus 183 
lactis strains. It has potent activity against many Gram-positive bacteria but has 184 
much less intrinsic activity against Gram-negative organisms (43-45). By itself, nisin 185 
does not induce growth inhibition of Gram-negative bacteria, since binding to lipid II 186 
– the main target – is prevented by the outer bacterial membrane (46). Therefore, 187 
studies have used different methods to overcome this problem by combining nisin 188 
with chelating agents like EDTA, antibiotics and engineered nisin peptides (47-52). 189 
These compounds can destabilize the outer membrane, allowing nisin to exert its 190 
damaging effect (53, 54).  191 
Several in vivo models have confirmed the potency of bacteriocins in providing CR.  192 
Lactobacillus salivarius UCC 118, which produces the bacteriocin Abp118, was able 193 
to significantly protect mice from infection by direct killing of Listeria monocytogenes, 194 
while an UCC 118 mutant could not, confirming the protective role of Abp118 against 195 
this food-borne pathogen (55).  196 
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Another example is Bacillus thuringiensis DPC 6431, which produces the bacteriocin 197 
thuricin (36). Thuricin targets several C. difficile strains, including the highly virulent 198 
PCR ribotype 027. In vitro, its activity was more potent than metronidazole, the 199 
common treatment for C. difficile infection (56). In a colon model system, 200 
metronidazole, vancomycin and thuricin all effectively reduced C. difficile levels. 201 
However, thuricin has the advantage of conserving gut microbiota composition. This 202 
is highly relevant, as a disturbed microbiota is associated with increased 203 
susceptibility to infection (57, 58). 204 
Enterobacteriaceae members can produce specific bacteriocins called colicins and 205 
one example, colicin FY, is encoded by the Yersinia frederiksenii Y27601 plasmid. 206 
Recombinant E. coli strains, capable of producing colicin FY, were shown to be highly 207 
effective against Yersinia enterocolitica in vitro (59). In vivo experiments were 208 
performed by first administering the recombinant E. coli strains, after which mice 209 
were infected with Y. enterocolitica. In mice with a normal gut microbiota the 210 
recombinant strains did not inhibit Y. enterocolitica infection, while infection was 211 
effectively reduced in mice pre-treated with streptomycin (59). This was most 212 
probably the result of increased colonization capacity of recombinant E. coli in the 213 
inflamed gut, while the normal gut microbiota provided sufficient CR to prevent E. 214 
coli colonization (59). 215 
Microcins are also produced by Enterobacteriaceae, but differ from colicins in 216 
several ways (60). For example, microcins are of much smaller size (<10 kDa) and 217 
microcin production is not lethal to the producing bacterium, in contrast to colicin 218 
production (60). E. coli Nissle 1917, capable of producing microcin M and microcin 219 
H47, could significantly inhibit Salmonella enterica serovar Typhimurium in vitro and 220 
in vivo (61). This inhibition was however only seen during intestinal inflammation, 221 
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during which S. Typhimurium expresses siderophores to scavenge iron from an iron-222 
depleted environment. As microcins are able to conjugate to siderophores and S. 223 
Typhimurium takes up the siderophore during iron scavenging, microcins are 224 
introduced into the bacterial cell in a Trojan-horse like manner (62). 225 
In silico identification of bacteriocin gene clusters shows that much remains to be 226 
discovered in this area, as 74 clusters were identified in the gut microbiota (63). Not 227 
all of these clusters may be active in vivo, but it illustrates the potential relevance of 228 
bacteriocin production by the gut microbiota to provide colonization resistance.  229 
 230 
Nutrient competition 231 
Bacteria have to compete for nutrients present in the gut. This is especially relevant 232 
for bacterial strains belonging to the same species, as they will often require similar 233 
nutrients. The importance of nutrient competition in providing CR has been shown in 234 
multiple studies using multiple E. coli strains (64-67). Indigenous E. coli strains 235 
compete with pathogenic E. coli O157:H7 for the amino acid proline (64). In fecal 236 
suspensions, depletion of the proline pool by high-proline-utilizing E. coli strains 237 
inhibited growth of pathogenic E. coli. This inhibition could be reversed by adding 238 
proline to the medium, thereby confirming nutrient competition between the strains 239 
(64). In addition to amino acids, different E. coli strains use distinct sugars present in 240 
the intestinal mucus (65). When two commensal E. coli strains were present in the 241 
mouse gut that together utilize the same sugars as E. coli O157:H7, E. coli O157:H7 242 
was unable to colonize after it was administered to these mice. However, E. coli 243 
O157:H7 successfully colonized when only one of these commensals was present. 244 
This indicated that the two commensals complement each other to sufficiently 245 
deplete all sugars used by this pathogenic E. coli strain (66). Nutrient competition is 246 
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not limited to macronutrients, but can extend to micronutrients such as iron. S.  247 
Typhimurium is known to take up large amounts of iron from the inflamed gut during 248 
infection (67). Upon a single administration of the probiotic E. coli Nissle 1917, which 249 
was proposed to scavenge iron very efficiently, S. Typhimurium levels were reduced 250 
more than two log-fold during infection via the limitation of iron availability. 251 
Administration of E. coli Nissle 1917 prior to infection with S. Typhimurium led to a 252 
445-fold lower colonization (67). 253 
Finally, genome-scale metabolic models have been used to reconstruct microbiome-254 
wide metabolic networks, which could partly predict which species utilize specific 255 
compounds from their environment (68). These models have been used to study 256 
nutrient utilization by C. difficile, which will be described in the section on this 257 
organism below.  258 
Together, these studies show that colonization resistance by nutrient competition is 259 
most effective when microbiota take up key nutrients that are required by the 260 
pathogen (Fig. 1). Future strategies could therefore aim at administrating probiotic 261 
strains that are able to outcompete pathogens for specific nutrients. This is 262 
especially relevant at times of gut microbiota disturbances, e.g. during and following 263 
an antibiotic treatment, as this is the time window where it is easiest for exogenous 264 
bacteria to colonize the GI tract. 265 
 266 
Mucus layers 267 
The gut barrier consists of the inner and outer mucus layer, the epithelial barrier and 268 
its related immune barrier. It is out of the scope of this review to discuss the full 269 
immunological characteristics of the epithelial barrier, the highly complex host-270 
microbe interactions occurring at the mucus layer and host-associated genetic 271 
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polymorphisms associated with mucus layer composition, as these have been 272 
extensively described elsewhere (12, 13, 69, 70). Instead, a general description with 273 
various examples of how the mucus layer provides CR will be given.  274 
The inner mucus layer is impenetrable and firmly attached to the epithelium, forming 275 
a physical barrier for bacteria thereby preventing direct interaction with the epithelial 276 
layer and a potential inflammatory response (71, 72). Commensal gut microbes 277 
reside and metabolize nutrients in the nonattached outer mucus layer. Thinning of 278 
the mucus layer leads to an increased susceptibility for pathogen colonization, which 279 
can result from a Western-style diet deficient in microbiota-accessible-carbohydrates 280 
(MACs) (58). When MACs were scarce, mucus-degrading bacteria (Akkermansia 281 
muciniphila and Bacteroides caccae) fed on the outer mucus layer in a gnotobiotic 282 
mouse model, resulting in closer proximity of bacteria to the epithelial layer (58). The 283 
host adapts by increasing muc2 expression, the main producer of intestinal mucin 284 
glycans, but fails to sufficiently do so. Inner mucus layer damage could however be 285 
reversed by administration of Bifidobacterium longum, perhaps due to stimulation of 286 
mucus generation (73).  287 
The composition of the microbiota is thus a contributing factor to the integrity of the 288 
mucus barrier. Genetically identical mice housed in different rooms at the same 289 
facility showed a distinct microbiota composition, with one group of mice showing a 290 
more penetrable barrier (74). When FMT was performed on germ-free mice, they 291 
displayed the same barrier function as their respective donor. No specific microbes 292 
were identified to be responsible for the change in observed barrier function (74). 293 
In conclusion, the mucus layers provide a first barrier of defense against colonization 294 
of exogenous microorganisms. Diet has been shown to be an important factor for 295 
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proper functioning of this layer, suggesting that dietary intervention, or specific pro- 296 
and prebiotics, may be a future therapeutic option. 297 
 298 
Bacteriophages  299 
Bacteriophages are the most abundant microorganisms on our planet and are also 300 
highly present in the human gut (75, 76). Bacteriophages have been proposed as 301 
potential alternatives to antibiotics, as they are highly specific, only targeting a single 302 
or a few bacterial strains thereby minimizing the impact on commensal members of 303 
the microbiota (75, 77) (Fig. 1). Their complex interactions in the intestine with both 304 
host immunity and bacterial inhabitants are starting to be explored, but much 305 
remains to be elucidated (76). Here, we will focus on their relationship with bacterial 306 
enteropathogens. 307 
Vibrio cholerae infection could be controlled using a prophylactic phage cocktail in 308 
mice and rabbits (78). This prophylactic cocktail killed V. cholerae in vitro, reduced 309 
colonization of V. cholerae in the mouse gut and prevented cholera-like diarrhea in 310 
rabbits. Importantly, the authors suggest that the concentration of phages in the gut 311 
is an important criterion for successful prevention of infection, as timing between 312 
phage cocktail administration and V. cholerae inoculation was associated with 313 
treatment outcome (78). Similar findings have been demonstrated for Campylobacter 314 
jejuni colonization in chickens, where a phage cocktail reduced C. jejuni levels 315 
several orders of magnitude (79).  316 
Bacteriophages can also confer a competitive advantage for commensals. 317 
Enterococcus faecalis V583 harbors phages that infect and kill other E. faecalis 318 
strains, thereby creating a niche for E. faecalis V583 (80). 319 
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Phages play an important role in excluding specific gut bacteria and can thereby 320 
contribute to CR. Therapeutic use in humans is not yet performed at a wide scale in 321 
the Western world, as sufficient evidence for their safety and efficacy is still lacking 322 
(81). However, recent case reports indicate that bacteriophage treatment has definite 323 
future potential for treating multi-drug resistant bacteria (82, 83). 324 
 325 
EFFECTS OF VARIOUS NON-ANTIBIOTIC DRUGS ON GUT COLONIZATION 326 
RESISTANCE 327 
Antibiotics are long known for their deleterious effect on gut microbiota. Recently, 328 
various other drugs have come to attention for their impact on our microbial 329 
ecosystem. As effects of antibiotics have been extensively reviewed elsewhere (84, 330 
85), the focus in the current review will be on non-antibiotic drugs, namely proton-331 
pump inhibitors (PPIs), antidiabetics and antipsychotics.  332 
 333 
Proton-pump inhibitors 334 
PPIs inhibit gastric acid production and are among the most prescribed drugs in 335 
Western countries (86). A significant association between long-term use of PPIs and 336 
the risk on several bacterial enteric infections has been demonstrated in multiple 337 
systematic reviews (87-90). 338 
Several studies have associated PPI use with microbiota alterations that may 339 
specifically predispose to C. difficile infection and to small intestinal bacterial 340 
outgrowth (91-95). Especially taxa prevalent in oral microbiota (e.g. Streptococcus) 341 
were associated with PPI use, likely resulting from increased gastric pH and thereby 342 
allowing for colonization of these bacteria further down the gastrointestinal tract (91-343 
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94). Administering  PPIs to twelve healthy volunteers for four weeks did not result in 344 
changes in diversity or changes in overall microbiota composition. However, 345 
abundance of specific taxa associated with C. difficile infection and gastrointestinal 346 
bacterial overgrowth increased, thereby potentially lowering colonization resistance 347 
against C. difficile (91).  348 
Results of two mouse studies suggest that the reduced bactericidal effect, due to 349 
increased stomach pH, may be the most important factor for increased enteric 350 
infection risk. Mice received PPIs seven days prior to infection with the murine 351 
pathogen Citrobacter rodentium, which resulted in increased numbers of C. 352 
rodentium in the cecum one hour post inoculation as compared to control mice (96). 353 
Similar results were observed in another study where treatment of mice with PPIs led 354 
to increased colonization of vancomycin-resistant enterococci and Klebsiella 355 
pneumoniae (97). In spite of its general acceptance as a model for gut disturbances, 356 
it is important to note that mice were pre-treated with clindamycin, which may limit 357 
generalizability (97). This is an important issue when studying effects of PPIs, as the 358 
combined use of medication in the human population complicates the study of the 359 
effects of PPIs on microbiota and CR. Even though large-scale studies have 360 
adjusted for cofounders to filter out the effect of PPIs on the gut microbiota, this does 361 
not represent a mechanistic study where only PPIs would be administered (92, 98). 362 
Therefore, more mechanistic studies investigating how PPIs increase the risk for 363 
enteric infection are required. These studies should then exclusively administer PPIs 364 
to healthy human volunteers or animals.  365 
 366 
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Antidiabetics  367 
Metformin is the primary prescribed drug for treatment of type II diabetes mellitus 368 
(T2DM) and mainly acts by reducing hepatic glucose production, thereby lowering 369 
blood glucose levels (99). The current increase in the number of T2DM patients is 370 
unprecedented and it is therefore crucial to evaluate metformin’s effect on gut 371 
microbiota and colonization resistance (100). 372 
The microbiota of T2DM patients is, amongst other changes, characterized by a 373 
depletion in butyrate-producing bacteria (101, 102). Metformin administration 374 
increased both the abundance of butyrate and other SCFA-producing bacteria, as 375 
well as fecal SCFA levels and may thus contribute to colonization resistance. The 376 
underlying mechanisms remain unknown (101, 103).  377 
Another effect of metformin has been studied in an in vitro model, where it was found 378 
to reduce tight junction dysfunction of the gut barrier by preventing TNF-α induced 379 
damage to tight junctions (104). Similar findings for improvement of tight junction 380 
dysfunction were demonstrated using two in vivo models, one using interleukin-10 381 
deficient mice and one using a colitis mouse model (105, 106). As tight junctions are 382 
a critical part of epithelial barrier integrity, alleviating their impaired functioning likely 383 
improves CR. 384 
In conclusion, metformin may have beneficial effects on CR, as its ability to raise 385 
SCFA concentrations and improved tight junction function suggests. The effects of 386 
metformin on gut microbiota and CR in healthy organisms needs further evaluation. 387 
 388 
Antipsychotics 389 
The interest in whether antipsychotics affect gut microbiota composition and 390 
colonization resistance may surge after a recent publication demonstrating that 391 
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antipsychotics target microbes based on their structural composition (107). This led 392 
to the suggestion that antibacterial activity may not simply be a side effect of 393 
antipsychotics, but can be part of their mechanism of action (107). Various 394 
antipsychotics have been investigated for their antibacterial effects, of which several 395 
will be highlighted here.  396 
In an in vitro model, olanzapine has been demonstrated to completely inhibit growth 397 
of two potentially pathogenic bacteria, E. coli and E. faecalis (108). Pimozide has 398 
been shown to inhibit internalization of several bacteria, including L. monocytogenes 399 
(109). An in vitro screening test evaluated effects of fluphenazine on 482 bacterial 400 
strains, belonging to ten different genera. Growth inhibition was demonstrated in 401 
multiple species, including five out of six Bacillus spp., 95 out of 164 staphylococci, 402 
138 out of 153 V. cholerae strains and several Salmonella species. Significant 403 
protection by administering fluphenazine was shown in a mouse model infected with 404 
S. Typhimurium, as viable cells in several organs was lower and overall survival was 405 
higher as compared to controls (110).  406 
Antipsychotics can also be used in combination with antibiotics, to exert a synergistic 407 
antibacterial effect. Flupenthixol dihydrochloride (FD) was demonstrated to have 408 
antibacterial activity, both in vitro and in vivo (111). Co-administration of FD and 409 
penicillin yielded extra protection against S. Typhimurium as compared to singular 410 
administration of either drug. (111). As antipsychotics have only recently been 411 
recognized for their potential antimicrobial effects, studies have only looked at the 412 
effects on pathogens. It is likely that gut commensals are also affected by these 413 
drugs, but future studies will have to confirm this hypothesis.  414 
Apart from their potential antibacterial effects, several antipsychotics were shown to 415 
increase intestinal permeability in the distal ileum in rats, and therefore showing a 416 
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possibly detrimental effect on CR (112). Curiously enough, use of antidepressants 417 
was associated with increased risk of C. difficile infection development, although no 418 
underlying mechanism has been elucidated yet (113). 419 
In conclusion, antipsychotics have definite antibacterial effects, but, to our 420 
knowledge, no studies have yet been performed regarding their effects on 421 
colonization resistance and bacterial enteric infection in vivo. 422 
 423 
COLONIZATION RESISTANCE TOWARDS SPECIFIC BACTERIAL ENTERIC 424 
PATHOGENS 425 
Other than antibiotic resistance acquisition, enteric pathogens possess multiple 426 
virulence factors to overcome CR and cause infection. Some of these factors are 427 
common and apply to many bacterial species, others are organism-specific. 428 
Mechanisms implicated in antibiotic resistance development include horizontal gene 429 
transfer, mutational resistance and altering structure and thereby efficacy of the 430 
antibiotic molecule. Full reviews describing these mechanisms in depth can be found 431 
elsewhere (114, 115). Here, the main focus will be on how several of the most 432 
prevalent and dangerous bacterial enteropathogens overcome the mechanisms 433 
providing CR as described herein, namely secretion of antimicrobial products, 434 
nutrient competition, mucus barrier integrity and bacteriophage deployment. As 435 
insufficient knowledge is available on how each specific enteropathogen overcomes 436 
CR by rendering bacteriophages ineffective, apart from the well-known and 437 
conserved CRISPR-Cas, an overview of the currently known bacterial defense 438 
mechanisms will be given at the end of this review.  439 
 440 
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C. difficile  441 
C. difficile-associated diarrhea is the most common hospital-acquired infection, 442 
causing more than 450.000 diarrheal cases per year in the United States alone 443 
(116). Clinical symptoms can range from self-limiting diarrhea to bloody diarrhea, 444 
pseudomembranous colitis and ultimately death (117). However, also in healthy 445 
individuals CR is not always successful against this opportunistic pathogen, resulting 446 
in asymptomatic colonization in 2-15% of the healthy population (118). The reason 447 
why some asymptomatically colonized patients do not develop infection, while others 448 
do, may well be found in the gut microbiome, although no mechanisms have yet 449 
been elucidated. C. difficile contains a pathogenicity locus with the information to 450 
produce its two major toxins, TcdA and TcdB. The significance of a third toxin, called 451 
binary toxin, is less clear. Toxin production in the colon is facilitated by disruption of 452 
the native gut microbiota, for instance through antibiotic use (119). 453 
 454 
Effects of SCFAs on C. difficile throughout its life cycle are currently unclear (120-455 
122). In an antibiotic-treated mouse model, decreased SCFA levels were associated 456 
with impaired CR against C. difficile (120). CR was subsequently restored six weeks 457 
after ending antibiotic treatment with a concomitant increase in SCFAs, probably 458 
resulting from restoration of the fermentative activity of the microbiota (120). 459 
Restoration of SCFA levels is also seen as an effect after fecal microbiota 460 
transplantations in humans (122). However, SCFA supplementation could not induce 461 
a significant decrease in C. difficile shedding levels up to six weeks post infection 462 
(121). No study has yet investigated whether C. difficile possesses any mechanisms 463 
by which it becomes resistant against the effects of SCFAs, which warrants further 464 
research.  465 
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 466 
Compared to the effects of SCFAs, there is more clarity on the effects of bile acids 467 
on C. difficile. Secondary bile acids are toxic to both C. difficile spores and vegetative 468 
cells, while primary bile acids generally stimulate growth and spore germination 469 
(123-125). During antibiotic treatment, conversion of primary into secondary bile 470 
acids is suppressed and the reduction of secondary bile acids leads to a more 471 
favorable environment for C. difficile (120).In addition, C. difficile isolates causing 472 
most severe disease in mice were also the isolates that showed highest resistance 473 
against lithocholic acid in vitro (126). A relationship between disease score and 474 
deoxycholic acid could not be shown (126). Secondary bile acid resistance may be 475 
strain-dependent, but further research is warranted to draw this conclusion with 476 
certainty. 477 
 478 
Intrinsic anti-bacteriocin properties have been described for C. difficile (127, 128). 479 
Nisin can inhibit growth of vegetative cells and prevent spore germination of C. 480 
difficile in vitro (44). However, this does not hold for all C. difficile strains, as the 481 
mutant strain MC119 had normal growth in sub-lethal concentrations. It was 482 
demonstrated that this resistance was at least partly due to export of nisin by an 483 
ABC-transporter (127). Another identified mechanism was a net positive charge on 484 
the bacterial cell surface resulting in lower efficacy of nisin, since nisin is attracted to 485 
a low negative charge on the cell surface (128). 486 
 487 
Using genome-scale metabolic models in antibiotic-treated mice, it was 488 
demonstrated that C. difficile does not necessarily compete for specific nutrients 489 
against specialized bacteria, but that it adapts to utilize a wide array of nutrients. This 490 
21 
 
allows for colonization of diverse microbiomes, wherein C. difficile is not limited to a 491 
specific nutrient niche (129). A follow-up study, also using a multi-omics approach, 492 
showed that C. difficile alters transcriptional activity of especially low abundant taxa. 493 
The main genes showing decreased transcription in these low abundant taxa during 494 
infection, as compared to mock infected mice, were carbohydrate-acquisition and 495 
utilization genes. A possible reason for this could be that C. difficile attempts to 496 
create its own nutrient niche to facilitate colonization (130).  497 
However, others have found specific nutrients that may be important for C. difficile 498 
colonization and/or outgrowth. Three highly virulent ribotypes (RT), RT017, RT027 499 
and RT078, have recently been demonstrated to utilize trehalose as a nutrient 500 
source (131, 132). This was confirmed in a mouse model, where mice were 501 
challenged with spores of either RT027 or a non-trehalose metabolizing ribotype. 502 
After trehalose administration, RT027 mice showed higher mortality in a dose-503 
dependent manner (131).  504 
C. difficile post-antibiotic outgrowth depends partly on the production of succinate 505 
and sialic acid by commensals. B. thetaiotaomicron is capable of metabolizing 506 
polysaccharides and thereby produces sialic acid. Upon inoculation with C. difficile, 507 
monocolonized B. thetaiotaomicron mice had approximately a five times higher 508 
density of C. difficile in feces as compared to germ-free mice (133). Expression 509 
levels of genes involved in sialic acid metabolism were increased in the B. 510 
thetaiotaomicron model, and, as expected, a sialidase-deficient B. thetaiotaomicron 511 
mutant led to highly reduced production of sialic acid and C. difficile density was 512 
lower (133). 513 
Density of C. difficile was higher in B. thetaiotaomicron mice fed a polysaccharide-514 
rich diet as compared to a chow diet (134). The succinate to butyrate pathway was 515 
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crucial for C. difficile expansion in B. thetaiotaomicron mice, as WT C. difficile was 516 
more effective in establishing infection than a succinate-transporter deficient C. 517 
difficile (134).  518 
Micronutrient availability can affect virulence of C. difficile. High zinc levels have 519 
been demonstrated to exacerbate C. difficile infection in mouse models (135). Mice 520 
fed a high-zinc diet had higher toxin levels, higher pro-inflammatory cytokines levels 521 
and increased loss of barrier function. Furthermore, it was shown that calprotectin, a 522 
zinc-binding protein, was important for limiting zinc availability to C. difficile during 523 
infection (135).  524 
Together, these studies demonstrate the importance of specific nutrients used by C. 525 
difficile to establish colonization and infection. 526 
 527 
Efficient colonization of the epithelial barrier is made possible by flagella and pili 528 
(136, 137). When mice were inoculated with flagellated or non-flagellated C. difficile 529 
strains, higher levels of flagellated C. difficile were found in mouse cecum (136). The 530 
exact destination of non-flagellated C. difficile remained unknown, as levels were not 531 
measured in feces or in sections of the small intestine. Regarding pili, it has been 532 
shown that type IV pili were not playing a role in initial colonization, but were crucial 533 
for epithelial adherence and long-lasting infection (137).  534 
 535 
S. Typhimurium  536 
S. Typhimurium is a nontyphoidal Salmonella and an important cause of 537 
gastroenteritis in humans. It was estimated that globally 3.4 million invasive 538 
nontyphoidal Salmonella infections occur each year, of which 65.2% are attributable 539 
to serovar Typhimurium (138). It mostly causes self-limiting, non-bloody diarrhea in 540 
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otherwise healthy individuals. However, it can lead to bloodstream infections and 541 
metastatic spread with eventually death in especially infants and 542 
immunocompromised individuals (138, 139). S. Typhimurium contains two 543 
pathogenicity islands, SPI1 and SPI2. SPI1 mostly contains information for causing 544 
intestinal disease and cell invasion, while SPI2 is necessary for intracellular survival 545 
(140).  546 
 547 
Effects of SCFAs on S. Typhimurium are not yet well defined. Butyrate and 548 
propionate have been demonstrated to reduce expression of invasion genes, while 549 
acetate increased their expression in S. Typhimurium (141, 142). However, 550 
conflicting results exist. A S. Typhimurium knockout mutant, unable to metabolize 551 
butyrate, caused less inflammation than a WT S. Typhimurium, suggesting that 552 
butyrate is crucial for S. Typhimurium virulence (143). Furthermore, this study 553 
demonstrated that butyrate was necessary for expression of invasion genes in 554 
mouse models. In contrast, propionate inhibited S. Typhimurium in a dose-555 
dependent manner in vitro, probably due to disturbance of intracellular pH (144). In 556 
an in vivo setting, it was demonstrated that a cocktail of propionate-producing 557 
Bacteroides species was sufficient to mediate CR against S. Typhimurium (144). 558 
 559 
S. Typhimurium has developed mechanisms to overcome bile acids encountered in 560 
the gut. When exposed to individual bile acids at sub-lethal levels in vitro, it can 561 
become resistant to originally lethal levels by changing gene and protein expression 562 
of several virulence regulators (145, 146). In addition, it has been demonstrated that 563 
a mixture of cholate and deoxycholate confers a synergistic inhibition on invasion 564 
gene expression in S. Typhimurium (147).  565 
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 566 
Innate resistance of S. Typhimurium against bacteriocins produced by Gram-positive 567 
bacteria is naturally conferred through its Gram-negative outer membrane (148).  568 
 569 
Usage of nutrients produced by gut microbiota is believed to facilitate S. 570 
Typhimurium outgrowth. By causing inflammation and thereby altering microbiota 571 
composition, S. Typhimurium provides itself with a competitive advantage (149, 150).  572 
Metabolic profiling in mice showed increased luminal lactate levels in the inflamed 573 
gut during S. Typhimurium infection, which could result from a depletion in butyrate-574 
producing bacteria (149). When butyrate is scarce, enterocytes switch to glycolysis 575 
with lactate as end product. Lactate is an important nutrient for S. Typhimurium, as 576 
indicated by decreased colonization of cecal and colonic lumen by a S. Typhimurium 577 
mutant lacking two lactate dehydrogenases (149).  578 
As explained in the introduction,  an anaerobic milieu is maintained in the gut during 579 
homeostatic conditions. However, diffusion of oxygen from the tissue to the lumen is 580 
enabled by inflammation caused by S. Typhimurium, which alters enterocyte 581 
metabolism (151). Oxygen can then be used by S. Typhimurium to ferment several 582 
carbohydrates through respiration (152-155).  583 
In conclusion, these findings suggest that S. Typhimurium creates its own niche in 584 
the gut by causing inflammation, subsequently shifting microbiota composition and 585 
thereby nutrient availability, so that it can optimally colonize and expand. 586 
 587 
An intact and well-functioning mucus layer is crucial for protection against S. 588 
Typhimurium infection. WT mice infected with the attenuated ΔaroA strain, which 589 
causes severe colitis, showed increased muc2 gene expression and MUC2 590 
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production (156). Mortality and morbidity was high in Δmuc2 mice and higher 591 
numbers of the pathogen were found in their liver, ceca and close to the epithelial 592 
layer (156).  593 
S. Typhimurium may profit from mucin-degrading commensal microbiota. In a 594 
gnotobiotic mouse model, complementation with mucin degrading A. muciniphila 595 
during S. Typhimurium infection allowed S. Typhimurium to dominate the bacterial 596 
community five days p.i (157). This was not caused by an absolute increase in cell 597 
number, but by a decrease in other microbiota members. In addition, the 598 
complementation with A. muciniphila led to increased inflammation, as indicated by 599 
increased histopathology scores and protein and mRNA levels of pro-inflammatory 600 
cytokines. Although generally considered a beneficial bacterium, A. muciniphilia 601 
exacerbated S. Typhimurium infection by thinning the mucus layer, thereby 602 
promoting translocation of the pathogen to the epithelial layer (157).  603 
 604 
Enterohemorrhagic E. coli  605 
Shiga-toxin producing E. coli (STEC) comprises a group of E. coli strains capable of 606 
producing Shiga-toxins. Enterohemorrhagic E. coli (EHEC) is a subgroup of STEC 607 
causing more severe disease, often with complications. Each year, approximately 608 
100,000 people are infected by the most common EHEC serotype, O157:H7 (158). 609 
Clinical presentation includes abdominal pain and bloody diarrhea which can 610 
progress into toxin-mediated hemolytic uremic syndrome (159). Virulence of EHEC 611 
strains is mostly encoded by Shiga toxin genes, stx1 and stx2,  and by locus of 612 
enterocyte effacement (lee) genes, which are imperative for initial attachment to 613 
epithelial cells (160). 614 
 615 
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At present, outcomes regarding the effects of SCFAs on EHEC are mixed (161-165). 616 
LEE protein and gene expression was already enhanced at 1.25mM of butyrate, 617 
while for acetate and propionate, only minor changes were detected at 20mM, with 618 
acetate giving a repressive effect. In a separate growth experiment, acetate was 619 
more efficient in inhibiting growth of EHEC as compared to butyrate and propionate 620 
(162). Acetate was observed to have small repressive effects on EHEC in the study 621 
by Nakanishi et al., and this was also found by Fukuda et al. (162, 165). Mice fed 622 
acetylated starch prior to infection showed higher fecal acetate levels and improved 623 
survival rate compared to starch-fed mice (165). Acetate also prevented gut barrier 624 
dysfunction as measured by transepithelial electrical resistance and prevented 625 
translocation of the Shiga toxin to the basolateral side of the epithelial cells (165). 626 
In Caco2 cells, EHEC epithelial adherence was 10-fold higher when grown on 627 
butyrate than on acetate or propionate (162). These results indicate that butyrate 628 
may be less effective in inhibiting EHEC growth and potentially colonization as 629 
compared to acetate and propionate, for which the exact pathways and genes 630 
involved have been elucidated (162, 163).  631 
In contrast, butyrate was found to be effective against EHEC in a pig model (161). 632 
Piglets given sodium butyrate two days prior to being infected with EHEC showed no 633 
symptoms 24 hours p.i, while the control group developed multiple signs of disease, 634 
e.g. histopathological signs of kidney damage. The sodium butyrate group did not 635 
show any signs of inflammation and shed less viable cells compared to the control 636 
group within 48h (161). In vitro assays demonstrated that butyrate enhanced 637 
bacterial clearance, ultimately making the authors suggest that butyrate can be 638 
developed as a new drug to treat EHEC (161).  639 
 640 
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EHEC has multiple traits to fight against the potentially deleterious effects of bile 641 
acids. Bile acid mixtures upregulated gene expression of the AcrAB efflux pump and 642 
downregulated ompF, a gene encoding for an outer membrane porin (166). In 643 
addition, other genes responsible for limiting penetration of bile acids through the 644 
membrane (basR and basS), were upregulated, and this effect was concentration-645 
dependent. Interestingly, the bile acid mixtures did slightly downregulate stx2 subunit 646 
genes, encoding for Shiga toxin production (166).  647 
 648 
EHEC possesses natural resistance against bacteriocins, especially nisin, through its 649 
Gram-negative outer membrane, as described in the chapter on bacteriocins. Three 650 
EHEC strains were screened for, amongst others, potential resistance against 651 
several colicinogenic E. coli strains (167). In vitro, resistance against E. coli strains 652 
producing a single colicin was observed, but resistance was rarely observed against 653 
multiple colicins and could never be linked to acquiring a specific plasmid (167).  654 
 655 
Nutrient competition for proline and several sugars between EHEC and commensal 656 
E. coli strains is described in the introductory section. In addition, ethanolamine (EA), 657 
a source of carbon, nitrogen and energy for EHEC, has been investigated. It was 658 
demonstrated that EA could diffuse across the bacterial membrane and that the eut 659 
genes were crucial for metabolizing EA. Eut sequences were absent in native 660 
bacterial genomes in the bovine gut, apart from commensal E.coli, indicating that EA 661 
provides a nutrient niche for E. coli. When the eutB gene was knocked out in 662 
EDL933, it was outcompeted by commensal E. coli due to its inability of utilizing EA, 663 
indicating its critical importance for colonization (168).  664 
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During further transcriptomic investigations of EA utilization, it was noticed that 665 
genes involved in gluconeogenesis were upregulated if no glucose was 666 
supplemented. A knockout of two genes within the gluconeogenesis pathway led to a 667 
growth defect in a coculture with the wildtype (169). This is in line with a previous 668 
finding that optimal usage of gluconeogenic substrates by EDL933 is important for 669 
colonization (170). Since this effect was seen in a medium consisting of bovine small 670 
intestinal contents, the relevance for the human gut remains unclear (169).  671 
Co-culturing of EHEC with B. thetaiotaomicron led to an upregulation of genes 672 
involved in nutrient competition in EHEC as compared to culturing EHEC alone 673 
(171). In addition, presence of B. thetaiotaomicron resulted in upregulation of 674 
multiple virulence genes including lee, likely due to regulation of a transcription factor 675 
involved in sensing carbon metabolite concentrations in the environment (171). 676 
Using a combination of in vitro and in vivo methods, Pacheco et al. showed that 677 
fucose cleaved from mucins by B. thetaiotaomicron could be an important nutrient for 678 
upregulating virulence and intestinal colonization of EHEC (172). Interestingly, 679 
fucose sensing and subsequent regulation of virulence genes was more important 680 
for successful colonization than utilization of fucose for energy. This example 681 
indicates that nutrients cannot only be utilized for energy, but that they can be 682 
important environmental signals for properly regulating timing of virulence (172).  683 
 684 
Human colonoid monolayers were used to study initial colonization mechanisms of 685 
EHEC (173). This study showed that EHEC disturbs the tight junctions, preferentially 686 
attaches to mucus producing cells and subsequently impairs the mucus layer (173). 687 
In addition, by using various in vitro models, it was demonstrated that the 688 
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metalloprotease StcE, produced by EHEC, enables degradation of MUC2 in the 689 
inner mucus layer which may pave the way to the epithelial surface (174).  690 
 691 
S. flexneri  692 
Shigella infections mostly occur in developing countries, with S. flexneri as the most 693 
frequently found species (175). Annually, an estimated 164,000 people die of 694 
shigellosis worldwide (176). Clinical presentation includes a wide variety of 695 
symptoms, including severe diarrhea, possibly containing blood and mucus, and 696 
abdominal pain (160). S. flexneri contains a virulence plasmid (pINV) which is 697 
necessary for invasion of epithelial cells and intracellular survival (160).  698 
 699 
No studies seem to have investigated resistance mechanisms of S. flexneri against 700 
SCFAs yet. Butyrate has been investigated as a potential therapeutic agent as it 701 
counteracts a putative virulence mechanism of S. flexneri, namely decreasing LL-37 702 
expression in the gut (177, 178). By suppressing LL-37 expression S. flexneri is able 703 
to colonize deeper into intestinal crypts (178). Butyrate was able to increase rectal 704 
LL-37 expression in a subgroup of patients, which was associated with lower 705 
inflammation in rectal mucosa and lower levels of pro-inflammatory cytokines (177). 706 
However, butyrate treatment did not seem to impact clinical recovery (177). 707 
 708 
The type three secretion system (T3SS) which is able to directly inject bacterial 709 
protein into host cells and cause infection, is considered a key virulence factor. S. 710 
flexneri T3SS can sense and bind secondary bile acid deoxycholate, which leads to 711 
co-localization of protein translocators at the needle tip (179, 180). In S. flexneri 712 
mutants lacking the needle structure, the deoxycholate-associated adhesion and 713 
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invasion of S. flexneri to host epithelial cells was diminished (181). At physiological 714 
levels of bile salts, S. flexneri is able to grow normally in vitro, but at increased 715 
concentrations growth is significantly reduced (182). Transcriptomics showed that 716 
during exposure to physiological bile salt levels, genes involved in drug resistance 717 
and virulence were upregulated, which was subsequently confirmed using RT-qPCR. 718 
Deletion of a multidrug efflux pump led to sensitivity to bile salts and growth inability, 719 
confirming the importance of this pump in bile salt resistance (182).  720 
 721 
Bacteriocin resistance has not been well studied in S. flexneri, but downregulating 722 
antimicrobial peptide production in the gut is suggested to be an important virulence 723 
mechanism (183). The downregulation of LL-37 early in infection was demonstrated 724 
both in gut biopsies of patients and in cell lines (183). Since protein and gene 725 
expression were not downregulated to the same degree, the authors speculated that 726 
there is an interference mechanism during active transcription of LL-37. Transcription 727 
of other antimicrobial peptides was also downregulated, especially in the human β-728 
defensin hBD family (178, 183). It was demonstrated that S. flexneri shows high 729 
sensitivity to LL-37 and hBD-3 peptides in vitro (178). This suggests that by 730 
downregulating expression of antimicrobial peptides, S. flexneri creates an 731 
environment in which it can survive and ultimately cause severe disease.  732 
It is unknown how S. flexneri competes and utilizes nutrients in the luminal side of 733 
the gut. Therefore, a short description will be given on how the bacterium rewires 734 
host cell metabolism for supporting its survival after entering the host cells. These 735 
findings might be translatable, and can at least provide insight in potential nutrient 736 
usage of S. flexneri in the lumen. Using a combination of metabolomics and 737 
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proteomics it was demonstrated that S. flexneri does not alter host cell metabolism in 738 
HeLa cells, but that it captures the majority of the pyruvate output (184). Pyruvate 739 
was demonstrated to be a crucial carbon source for S. flexneri cultured on a HeLa 740 
derivative, using metabolomics, transcriptomics and bacterial mutants (185). S. 741 
flexneri converts pyruvate into acetate via a very quick, but energy-inefficient 742 
pathway, allowing for rapid expansion of the bacterium intracellularly without rapid 743 
destruction of the host cell (184).  744 
 745 
S. flexneri possess special systems to alter mucus composition. Human colonoid 746 
monolayers infected with S. flexneri showed increased extracellular release of 747 
mucins (186). The increased extracellular mucins were trapped at the cell surface 748 
which surprisingly favored access of S. flexneri to the apical surface, subsequently 749 
promoting cell invasion and cell-to-cell spread (186). Furthermore, expression of 750 
several genes encoding for production of mucins and mucin glycosylation patterns 751 
were altered (186). Together, these results suggest that S. flexneri can alter the 752 
mucus environment such that it can promote its own virulence. 753 
C. jejuni  754 
C. jejuni is associated with food-borne gastroenteritis and is estimated to cause more 755 
than 800,000 infections annually in the USA alone (187). Major clinical symptoms 756 
include diarrhea (both with and without blood), fever and abdominal cramping (160). 757 
In rare cases, it can give rise to the Guillain-Barré syndrome and reactive arthritis 758 
(187). It is a commensal bacterium in avian species and it is not yet well understood 759 
why it causes disease in humans (188). 760 
 761 
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There is a distinct lack of research on the resistance mechanisms of C. jejuni against 762 
SCFAs, but one study found that SCFAs are important for colonization in chickens 763 
(189). Acetinogenesis, the conversion of pyruvate to acetate, is a crucial metabolic 764 
pathway for optimal colonization of C. jejuni. Mutants unable to use this pathway 765 
show impaired colonization and decreased expression of acetinogenesis genes. 766 
Upon encountering a mixture of SCFAs at physiological levels, this mutant was 767 
surprisingly able to restore acetinogenesis gene expression to WT levels. Therefore, 768 
it was investigated whether expression of acetinogenic genes differs throughout the 769 
intestinal tract, as SCFAs are most abundant in distal parts of the intestine. It was 770 
observed that both gene expression and C. jejuni levels were highest in the cecum. 771 
The authors suggested that C. jejuni can monitor SCFA levels in the gut, so that in 772 
response it can express colonization factors (189). As this is the only study 773 
suggesting this hypothesis, further research is required for validation.  774 
 775 
Results regarding bile acid resistance in C. jejuni are mixed, which may stem from 776 
using different animal models or bile acids. A specific multidrug efflux pump, 777 
CmeABC, was important for bile resistance in chickens (190). ΔcmeABC mutants 778 
showed impaired growth in vitro and unsuccessful colonization in chicken upon 779 
cholate administration, while cholate did not affect growth and colonization of the WT 780 
(190). This suggests that the efflux pump is critical for proper colonization of C. jejuni 781 
by mediating bile-acid resistance.  782 
Another study elucidated the effects of secondary bile acids on C. jejuni (191). Upon 783 
administration of deoxycholate prior to, and during, infection, mice showed 784 
decreased colitis. Unexpectedly, C. jejuni luminal colonization levels were not 785 
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affected (191). In conclusion, C. jejuni colonization seems not to be affected by bile 786 
acids, but may be important in limiting disease progression.  787 
 788 
Bacteriocin resistance is not common in C. jejuni. Multiple C. jejuni (n=137) isolates 789 
were screened for resistance against two anti-Campylobacter bacteriocins, OR-7 790 
and E-760, produced by the gut inhabitants L. salivarius and Enterococcus faecium. 791 
However, no isolates were found to harbor resistance (192). In a follow-up study, 792 
chickens were successfully colonized with a C. jejuni strain prior to bacteriocin 793 
treatment, with the aim of studying bacteriocin resistance. Resistance developed in 794 
most chickens, but was lost upon ending bacteriocin administration, suggesting 795 
resistance instability in vivo (193).  796 
 797 
In contrast to most other enteric pathogens, C. jejuni does not metabolize 798 
carbohydrates as its main energy source. It is unable to oxidize glucose, fructose, 799 
galactose and several disaccharides, including lactose, maltose and trehalose, 800 
resulting from the absence of 6-phosphofructokinase (194-197). Fucose could be 801 
metabolized by some C. jejuni strains, due to the occurrence of an extra genomic 802 
island (197). Main energy sources for C. jejuni are organic acids, including acetate, 803 
and a limited number of amino acids (198-200). It is currently unclear what these 804 
metabolic adaptations mean for its colonization potential, but it is possible that C. 805 
jejuni occupies a unique macronutrient niche. 806 
Iron regulation systems are critical for colonization and persistence of C. jejuni. In 807 
presence of sufficient iron, transporter and acquisition genes are downregulated 808 
(201). Mutants lacking genes involved in either iron acquisition or transport were 809 
severely impaired in colonizing the chick gut (201). Free iron concentrations are 810 
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extremely low in the gut, which forces C. jejuni to utilize other iron sources. It was 811 
demonstrated that lactoferrin and transferrin can also be used for this purpose and 812 
molecular pathways have been described (202). In short, transferrin-bound iron can 813 
only be utilized if it is in close proximity to the bacterial cell surface. Thereafter, it is 814 
most likely that iron is freed from the bacterial cell surface proteins, transported 815 
across the outer membrane and subsequently internalized by an ABC-transporter 816 
(202). Additionally, both in an in vitro setting and in a controlled human infection 817 
model with C. jejuni the most upregulated genes were involved in iron acquisition 818 
(188, 203). These results suggest that iron regulation is maintained extremely well, 819 
and that C. jejuni can obtain sufficient iron even in a harsh environment as the gut. 820 
 821 
C. jejuni resides in the mucus layer prior to invading the epithelial cell. It can cross 822 
and reside here because of its powerful flagellum, which can change in conformation 823 
or rotation upon being challenged by higher viscosity (204, 205). C. jejuni can hereby 824 
cross the mucus layer at speeds which cannot be met by other enteric pathogens, 825 
and the flagellum can subsequently be used as an adhesin (205, 206).  826 
Another important characteristic for C. jejuni ’s success in crossing the mucus layer 827 
is its helix-shape. In a mouse model, a WT strain or either of two rod shaped C. 828 
jejuni bacteria, Δpgp1 or Δpgp2, were administered to cause infection (207). Rod-829 
shaped mutants were demonstrated to be mostly non-pathogenic, whereas the WT 830 
strain caused severe inflammation. Mutants were to some extent able to colonize the 831 
mucus layer, but could not cross it, explaining their non-pathogenicity (207).  832 
 833 
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V. cholerae 834 
V. cholerae is one of the first bacterial pathogens where the microbiota has been 835 
considered to play an important role against infection (208). It is mainly prevalent in 836 
contaminated brackish or salt water and can cause outbreaks, particularly during 837 
wars and after natural disasters. In the first two years following the earthquake in 838 
Haiti, 2010, more than 600,000 people were infected with V. cholerae serogroup O1, 839 
biotype Ogawa, resulting in more than 7,000 deaths (209). The clinical course is 840 
characterized by watery diarrhea, which can be so severe that it can result in 841 
dehydration, hypovolemic shock and death (210). V. cholerae colonizes the small 842 
intestine by employing the toxin-coregulated pilus, after which it can cause severe 843 
infection and clinical symptoms through cholera enterotoxin production (210).  844 
 845 
V. cholerae is able to utilize its acetate switch, the shift from elimination to 846 
assimilation of acetate, to increase its own virulence (211). In a Drosophila model, it 847 
was demonstrated that crbRS controlled the acetate switch, while acs1 was required 848 
for acetate assimilation (211). When either of these genes were knocked-out, 849 
mortality decreased. Competition experiments demonstrated that WT V. cholerae 850 
had a growth advantage over ΔcrbS when WT V. cholerae was administered in 851 
minority. This led the authors to suggest that acetate utilization may be important 852 
early in infection, when low levels of V. cholerae cells are present (211). 853 
Furthermore, acetate consumption led to dysregulation of host insulin signaling 854 
pathways, ultimately leading to intestinal steatosis and increased mortality. 855 
Dysregulation of host insulin signaling was not observed in ΔcrbS or Δacs1, further 856 
confirming the role of acetate in V. cholerae virulence (211). 857 
 858 
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V. cholerae has a master regulator, toxT, which can directly activate several 859 
virulence factors including toxin production. Cholera toxin production was reduced by 860 
97% when V. cholerae was grown in presence of bile, which could be reversed after 861 
growing the same cells in bile-free medium for a few hours (212). Ctx and tcpA, 862 
encoding for cholera toxin and the major structural unit of the toxin-coregulated pilus 863 
and regulated by toxT, were highly repressed during bile exposure (212). 864 
Additionally, motility was increased approximately 1.6-fold in presence of bile (212). 865 
To elucidate which exact components of bile acids were responsible for the 866 
repression of these virulence genes, bile was fractionated. It was found that several 867 
unsaturated fatty acids strongly repressed ctx and tcpA and that they upregulated 868 
expression of flrA, leading to increased motility (213). The reason for upregulation of 869 
flrA and downregulation of tcpA could be that the flagellum increases the speed of 870 
passing through the mucus layer, while the pilus would only slow it down. When 871 
lower concentrations of bile at the epithelial surface are encountered, expression can 872 
be reversed (214).  873 
Two outer membrane porins, OmpU and OmpT, are directly regulated by the master 874 
regulator toxR. Upon encountering bile acids, ompU and ompT are regulated in such 875 
a way that bile acid entrance is prevented (215, 216). Furthermore, ΔtoxR mutants 876 
are more sensitive to bile acids due to changed outer membrane composition (215). 877 
Recently, it was shown that toxR also regulates leuO (217). LeuO was demonstrated 878 
to confer bile resistance independent of the two porins, although its exact resistance 879 
mechanism is not yet elucidated (217). 880 
 881 
Bacteriocin resistance in V. cholerae has, to our knowledge, not been studied and 882 
future studies will have to reveal whether any resistance is present.  883 
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 884 
An important nutrient through which V. cholerae gains a competitive advantage is 885 
sialic acid, a component of the mucus layer. Using streptomycin pre-treated mice 886 
who were given a mutant strain defective in sialic acid transport (ΔsiaM) , it was 887 
shown that sialic acid is not required for initial colonization, but that it is important for 888 
persistent colonization (218). Competition assays of the two mutant strains in mouse 889 
intestine (small intestine, cecum and large intestine) showed that ΔsiaM was less fit 890 
to compete in each environment, further indicating the necessity of sialic acid 891 
utilization for niche expansion of V. cholerae (218). 892 
The El Tor strain may have a competitive advantage over ‘classical’ strains due to its 893 
differential carbohydrate metabolism (219). When grown in a glucose-rich medium, 894 
classical strains display a growth defect as compared to El Tor. It was observed that 895 
this was due to production of organic acids through glucose metabolism, leading to 896 
acidification of the medium. El Tor biotypes were found to produce acetoin, a neutral 897 
compound, and decrease organic acid production. This prevented acidification of the 898 
medium, leading to better growth. El Tor strains were also more successful in 899 
colonizing mice, especially when extra glucose was administered. The classical 900 
types were shown to be able to produce acetoin, but glucose only led to a minor 901 
increase in transcription of genes necessary for acetoin production (219). These 902 
studies have shown that specific metabolic pathways are used by V. cholerae to 903 
successfully colonize the gut. 904 
 905 
One of the first studies on how the mucus layer can potentially be crossed by V. 906 
cholerae was reported almost 50 years ago (220). Here, motile and non-motile 907 
strains were compared for pathogenicity after administration to mice. It was observed 908 
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that motile strains were almost always deadly 36 hours p.i, while most non-motile 909 
strains had a mortality of under 35% (220). One hypothesis offered by the authors 910 
was that together with mucinase, the flagellum could effectively pass the mucus 911 
barrier (220). Specific mucin degradation mechanisms employed by V. cholerae 912 
have been identified since, with hemagglutinin/protease (Hap), and TagA being the 913 
major ones (221-225). Presence of mucins, limitation of carbon sources and bile 914 
acids maximized production of Hap, while glucose could partly reverse this effect 915 
(221). This may indicate that during conditions as encountered in the gut, V. 916 
cholerae quickly aims to cross the mucus layer and be in close contact with the 917 
epithelial cells. TagA, which is similar to StcE as described for EHEC, is also capable 918 
of degrading mucin (222). In conclusion, V. cholerae has developed a way of 919 
sensing environmental conditions, and in response to these, is able to upregulate 920 
virulence factors which can degrade mucins. A simplified overview of V. cholerae 921 
virulence factors opposing CR can be found in Fig. 2.  922 
 923 
Y. enterocolitica 924 
Yersiniosis is mostly contracted through contaminated food or water with Y. 925 
enterocolitica, and its prevalence is much higher in developing countries than in 926 
high-income nations (160, 226). It is characterized by mild gastroenteritis, abdominal 927 
pain and is usually self-limiting, though pseudo-appendicitis illnesses can occur 928 
(160). Virulence is mostly conferred through presence of a 64-75 kb plasmid on 929 
which several virulence genes are present, including yadA, which is crucial for 930 
epithelial adherence (227).  931 
 932 
39 
 
Resistance of Y. enterocolitica against antibacterial compounds has not been much 933 
studied. One study investigated effects of SCFAs on Y. enterocolitica at 4°C, 934 
including acetic acid and propionic acid. Y. enterocolitica was less sensitive to acetic 935 
acid when cultured anaerobically as compared to anaerobic culturing. Propionic acid 936 
was similarly effective in inhibiting growth with both culture methods (228). Even 937 
though conditions like 4°C are not representative for the intestinal environment, this 938 
study might provide some initial clues on the effects of SCFAs on Y. enterocolitica. It 939 
is clear that more research is required to further elucidate potential resistance 940 
mechanisms.  941 
 942 
OmpR, a transcriptional regulator in Y. enterocolitica, is probably able to upregulate 943 
expression of the AcrAB-TolC efflux pump, which, in turn, is regulated by two 944 
components of the efflux pump, acrR and acrAB (229). A mixture of bile acids, but 945 
not the secondary bile acid deoxycholate, was found to be the strongest inducer of 946 
acR and acrAB (229). Whether the upregulation of these efflux pump components 947 
contributes to bile acid resistance, remains to be elucidated.  948 
 949 
Bacteriocin resistance is so far mostly unknown in Y. enterocolitica. WA-314 and 950 
8081 are both 1B:O8 strains that are highly infective in murine models (230). WA-951 
314 possesses a putative colicin cluster for colicin production, but no expression was 952 
observed in a spot-on-lawn assay with 8081 and the colicin-sensitive E. coli K12 953 
(230). It is likely that no specific resistance against colicin is present, as colicin has 954 
been shown to effectively inhibit Y. enterocolitica infections in vivo (59).  955 
 956 
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Like most other enteric pathogens, Y. enterocolitica has sophisticated systems to 957 
acquire sufficient iron. Using these systems, Y. enterocolitica may be more efficient 958 
at scavenging iron than commensal members, thereby providing itself with a 959 
competitive advantage. Y. enterocolitica expresses yersiniabactin, ybt, a highly 960 
efficient siderophore and a crucial component for lethality in mouse models (231, 961 
232). The exact mechanisms for iron uptake and transport have been extensively 962 
reviewed elsewhere (233). Proteomics analysis revealed that Y. enterocolitica 963 
serovar 1A, whose pathogenic role is unclear, uses different proteins to successfully 964 
scavenge iron, as it lacks the Ybt protein (234).  965 
Y. enterocolitica is the only pathogenic Yersinia species which can metabolize 966 
sucrose, cellobiose, indole, sorbose and inositol (235). Additionally, it can degrade 967 
EA and 1,2-PD by using tetrathionate as a terminal electron acceptor (235). 968 
 969 
Mucus layer invasion and adherence of Y. enterocolitica have been elucidated in 970 
great detail several decades ago (236-240). The YadA protein is used for initial 971 
attachment to the mucus (240). The preferential binding side on mucins is their 972 
carbohydrate moiety, but binding to mucin proteins is also possible under specific 973 
conditions (238). Y. enterocolitica uses a plasmid, pYV, with mucin-degradation 974 
enzymes to thin the mucus layer, facilitating crossing of the mucus layer (237, 240). 975 
Y. enterocolitica containing the pYV plasmid is not only able to successfully invade 976 
and degrade the mucus layer, but is also highly efficient in multiplying in this 977 
environment (240). After interacting with the mucus layer, its bacterial cell surface 978 
was altered so that Y. enterocolitica became less efficient in colonizing the brush 979 
border (240). This may be a host response mechanism to prevent Y. enterocolitica 980 
invasion in deeper tissues. In a rabbit infection model, persistent goblet cell 981 
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hyperplasia and increased mucin secretion was observed throughout the small 982 
intestine over 14 days (236). The extent of hyperplasia was associated with severity 983 
of mucosal damage, indicating a compensatory mechanism. Mucin composition 984 
changed in infected rabbits, with a decrease in sialic acid and an increase in sulfate 985 
(236).  986 
 987 
L. monocytogenes 988 
L. monocytogenes causes listeriosis, a food-borne disease. Listeriosis is not highly 989 
prevalent, with an estimated 23,150 people infected in 2010 worldwide, but has a 990 
high mortality rate of 20-30% (241). The most common syndrome is febrile 991 
gastroenteritis, but complications can develop, such as bacterial sepsis and 992 
meningitis (241). This is especially relevant for vulnerable patient groups, such as 993 
immunocompromised individuals, neonates and fetuses (242). Virulence genes are 994 
present on an 8.2-kb pathogenicity island, which includes internalin genes necessary 995 
for invading host cells (243). 996 
 997 
Culturing L. monocytogenes in presence of high levels of butyrate leads to 998 
incorporation of more straight-chain fatty acids in the membrane (244, 245). This is 999 
not a natural state for L. monocytogenes, as normally its membrane consists for a 1000 
very high percentage of branched-chain fatty acids. When subsequently exposed to 1001 
LL-37, it displays a survival defect as compared to bacteria not grown in presence of 1002 
butyrate (244). It was not elucidated whether this survival defect was due to 1003 
increased stress, altered membrane composition or differentially regulated virulence 1004 
factors. Effects of propionate on L. monocytogenes growth, metabolism and 1005 
virulence factor expression are dependent on temperature, oxygen availability and 1006 
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pH (246). Therefore, it is not possible to ascribe a general function to propionate in 1007 
relation to L. monocytogenes.  1008 
  1009 
L. monocytogenes possesses several bile acid resistance mechanisms, and in vitro 1010 
transcriptome and proteome analyses have provided insight into these. 1011 
Transcriptomics analysis revealed that in response to cholic acid, amongst others, 1012 
two efflux pumps were upregulated, mdrM and mdrT (247). BrtA was shown to 1013 
regulate expression of the efflux pumps, and to be able to sense bile acid levels. 1014 
Bacterial abundance was determined in multiple organs of mice infected with 1015 
knockout strains of either efflux pump, but not in the intestine (247). Proteomic 1016 
analyses found many changes in response to bile salts and included proteins 1017 
associated with efflux pumps, metabolism and DNA repair (248).  1018 
Bile salt hydrolases (BSH) are another way of combatting encountered bile acids. It 1019 
was demonstrated that all Listeria species which infect mammals showed BSH 1020 
enzyme activity. BSH was crucial during infection of guinea pigs, demonstrated by 1021 
the decreased ability of Δbsh to cause a persistent infection (249).  1022 
At decreased pH levels, e.g. in the duodenum, bile salts are more acidic and show 1023 
higher toxicity (250). However, this toxicity seems to be strain-dependent (251). The 1024 
strain responsible for a 2011 outbreak even displayed higher bile resistance at pH 1025 
5.5 than at 7.0, further indicating that bile susceptibility may be strain-dependent 1026 
(251). 1027 
As discussed in the introductory section on bacteriocins, the Abp118 bacteriocin 1028 
produced by L. salivarius, protected mice from L. monocytogenes infection (55). 1029 
However, several bacteriocins have been shown ineffective against L. 1030 
monocytogenes and responsible mechanisms have been partly elucidated. Innate 1031 
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nisin resistance has been associated with multiple loci (252). One crucial gene was 1032 
anrB, encoding for a permease in an ABC transporter. Loss of this gene resulted in 1033 
high sensitivity, not only to nisin, but also to several other bacteriocins (252). The 1034 
mannose phosphotransferase system (Man-PTS), encoded by mptACD, is a main 1035 
sugar uptake system and two of its outer membrane proteins, IIC and IID, can serve 1036 
as a class II bacteriocin receptor (253). In natural resistant and spontaneous 1037 
resistant strains, a reduced expression of mptC and mptD was observed, although 1038 
this could not be linked to receptor mutations (254). The mpt operon is partly 1039 
regulated by manR, and a manR mutant did not show any activation of the mpt 1040 
operon (255). Development of bacteriocin resistance was to some extent dependent 1041 
on available carbohydrates (256). Several sugar sources impaired growth of L. 1042 
monocytogenes when exposed to bacteriocin leucocin A. Increased sensitivity to 1043 
leucocin A was hypothesized to relate to sugar uptake by Man-PTS. When specific 1044 
sugars are present, cells may not downregulate this system even in presence of 1045 
bacteriocins, which possibly allows leucocin A to use the Man-PTS as a docking 1046 
molecule (256). Not only does L. monocytogenes display bacteriocin resistance, it 1047 
also produces a bacteriocin, Lysteriolysin S, which modifies the gut microbiota such 1048 
that intestinal colonization is promoted (257). Allobaculum and Alloprevotella, genera 1049 
known to contain SCFA-producing strains, were significantly decreased in mice 1050 
treated with Lysteriolysin S. L. monocytogenes strains unable to produce 1051 
Lysteriolysin S were impaired in competing with native gut microbiota and colonized 1052 
less efficiently (257). 1053 
 1054 
Most reports about metabolic adaptations of L. monocytogenes have logically 1055 
described intracytosolic adaptations, as L. monocytogenes replicates intracellularly 1056 
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(258). Limited information is available on nutrient competition of L. monocytogenes 1057 
inside the lumen. Comparison of genome sequences between colonizing Listeria and 1058 
non-colonizing Listeria led to identification of, amongst others, a vitamin B12-1059 
dependent 1,2-propanediol (1,2-PD) degradation pathway in colonizing Listeria, 1060 
dependent on the pduD gene (259). Mice were co-infected with a ∆pduD strain and a 1061 
WT strain. Within 3 hours after feeding, a large amount of the ∆pduD was shed in 1062 
feces and 21 hours later the number of viable cells decreased significantly. At ten 1063 
days p.i, the ∆pduD strain was completely cleared, while the WT strain shed for up to 1064 
four more days. This indicates that the ability to degrade 1,2-PD offers L. 1065 
monocytogenes a distinct competitive advantage (259). 1066 
 1067 
Multiple adhesins and internalins have been characterized which facilitate L. 1068 
monocytogenes retention in the mucus layer (260-263). InlB, InlC, InlL and InlJ were 1069 
demonstrated to bind to MUC2, but not to epithelial cell surface MUC1 (262, 263). 1070 
Histopathological analysis of a listeriosis rat model revealed that L. monocytogenes 1071 
was present in the mucus layer after less than 3 hours p.i (261). At this time point, 1072 
very few L. monocytogenes were present on the epithelial cells (261). 1073 
 1074 
Bacterial defense mechanisms against bacteriophages 1075 
As research investigating how each enteric pathogen overcomes CR by rendering 1076 
bacteriophages ineffective is still in its infancy, this general section will describe the 1077 
most employed resistance mechanisms. The bacteriophage infectious cycle involves 1078 
a lytic and a lysogenic cycle. Phages have to bind to a receptor on the bacterial 1079 
surface to be able to insert their genomic material, usually DNA, into the bacterial 1080 
cytoplasm and subsequently circularize their DNA (264). Here, lysogenic and lytic 1081 
45 
 
bacteriophages’ mechanisms start to branch (Fig. 3). Lytic phages start DNA 1082 
replication, assemble their proteins and pack their DNA into the typical 1083 
bacteriophage shape with a capsid head and tail. After sufficient replication, phages 1084 
use lytic enzymes to form holes in the bacterial cell membrane, eventually leading to 1085 
lysis of the cell and phage spreading. Lysogenic phages integrate their DNA in the 1086 
bacterial chromosome and become prophages. Reproduction is then ensured 1087 
through vertical transmission, and upon induction, prophages can also enter the lytic 1088 
cycle (265) (Fig. 3). In general, factors that induce the lytic phase are compounds or 1089 
conditions with bactericidal effects, e.g. a DNA damaging-agent (266).  1090 
 1091 
The first step for preventing bacteriophage infection is to prevent surface receptor 1092 
recognition. Outer membrane vesicles are produced by Gram-negative bacteria and 1093 
have several functions, including interbacterial communication (267). They have 1094 
highly similar surface composition as the bacterium and may thereby serve as 1095 
decoys for attacking phages (268) (Fig. 3). Indeed, V. cholerae outer membrane 1096 
vesicles were shown to neutralize a V. cholerae specific phage in a dose-dependent 1097 
manner (Fig. 2) (268). This effect was only seen when the O1 antigen, the 1098 
bacteriophage target on V. cholerae, was included in the outer membrane vesicle 1099 
structure (268).  1100 
V. cholerae possesses another mechanism to prevent O1 phage receptor 1101 
recognition (269) (Fig. 3). Two genes necessary for O1 biosynthesis were shown to 1102 
use phase variation to induce variation in the O1 antigen composition (269). Mutants 1103 
using phase variation were resistant to the O1 antigen phage, but displayed impaired 1104 
colonization in a mouse model (269). As the O1 antigen is an important virulence 1105 
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factor, e.g. for immune evasion, this demonstrates that enteric pathogens constantly 1106 
have to deal with multiple CR mechanisms (269). 1107 
 1108 
The second step in phage infection is injection of its DNA, and this can be prevented 1109 
by superinfection exclusion systems which are mostly coded by prophages (Fig. 3). 1110 
The E. coli prophage HK97 encodes for gp15, a probable inner transmembrane 1111 
protein (270). Remarkably, HK97 gp15 has putative homologues resembling the 1112 
YebO protein family in many Enterobacteriaceae (270). GP15 prevented DNA 1113 
injection into the bacterial cytoplasm by preventing proper formation of a complex 1114 
consisting of an inner membrane glucose transporter and part of the tape measure 1115 
protein (270, 271). This example illustrates how bacteria can incorporate phage DNA 1116 
to prevent itself against future phage attacks.  1117 
 1118 
DNA replication can be prevented by restriction-modification systems (Fig. 3). These 1119 
systems consist of a methyltransferase and a restriction endonuclease. Exogenous 1120 
DNA is not tagged by this methyltransferase, while ‘self’ DNA does get tagged (272, 1121 
273). Subsequently, non-tagged DNA can be cleaved. This system is viewed as a 1122 
primitive innate bacterial defense system. However, it was found that this system is 1123 
not perfect, as these restriction-modification systems can also attack self-DNA (274).  1124 
 1125 
Currently, many groups are actively investigating the adaptive bacterial immune 1126 
system CRISPR-Cas and this has been extensively reviewed elsewhere (275, 276). 1127 
CRISPR-Cas is present in about 45% of sequenced bacterial genomes, although it is 1128 
unknown if its prevalence is similar in gut bacteria (277, 278). In short, it consists of 1129 
CRISPR arrays, sets of short repetitive DNA elements with variable DNA sequences 1130 
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(spacers) separating the repetitive DNA sets, and of an operon of CRISPR 1131 
associated genes (Cas). Spacers are pieces of foreign DNA, derived from 1132 
bacteriophage DNA or other mobile genetic elements such as plasmids. The defense 1133 
mechanism consists of adaptation followed by expression and interference. During 1134 
adaptation, Cas proteins can recognize foreign phage DNA and integrate a piece of 1135 
this DNA as a new spacer into the CRISPR array. This allows the bacterium to build 1136 
an immunological memory of all phages it previously encountered. The expression 1137 
response entails transcription of the CRISPR array, followed by processing into 1138 
smaller RNA pieces (crRNAs). CrRNAs consist of two outer parts of repeated DNA 1139 
sequences, with a spacer in between. To form the eventual Cas-crRNA complex, 1140 
crRNAs are combined with at least one Cas protein. This complex then travels 1141 
through the bacterial cell and when it identifies a complementary DNA sequence, 1142 
representative for the previously encountered bacteriophage, it cleaves and 1143 
degrades this foreign DNA.  1144 
 1145 
In 2015, a novel phage resistance system was discovered, called bacteriophage 1146 
exclusion (BREX) (279). BREX is able to block DNA replication, but does not prevent 1147 
bacteriophage attachment to the bacterium (Fig. 3). It also uses methylation as 1148 
guidance to identify self and exogenous DNA, but is different from restriction-1149 
modification systems as it does not cleave exogenous DNA (279). Almost 10% of all 1150 
bacterial genomes sequenced were found to have this BREX, suggesting that it is 1151 
quite a conserved defense mechanism against bacteriophages (279). In spite of this 1152 
promising defense mechanism, no further papers have been released regarding 1153 
BREX functioning in e.g. pathogenic bacteria.  1154 
 1155 
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Bacterial cells can perform an apoptosis-like action called abortive infection, resulting 1156 
in death of the infected cell and hereby protecting surrounding bacterial cells (280) 1157 
(Fig. 3). These systems have not been much elucidated for enteric pathogens at a 1158 
molecular level, though, relevance of this system has been shown for the gut 1159 
bacteria S. dysenteriae and E. coli (281, 282). The abortive infection systems are 1160 
best studied in L. lactis, a bacterium widely used in production of fermented foods 1161 
(283). 1162 
 1163 
CONCLUDING REMARKS  1164 
Currently, bacterial enteric infections still cause a heavy disease burden worldwide. 1165 
For many bacterial pathogens, the virulence factors involved in infection are 1166 
understood, but less is known concerning the failure of gut microbiota to provide 1167 
colonization resistance against these enteropathogens. A more comprehensive 1168 
understanding of why the microbiota fail to confer sufficient CR could lead to 1169 
development of specific therapies aiming to restore CR. It is likely that not a single 1170 
bacterium will be used as the ‘holy grail’ to restore CR, but that bacterial consortia 1171 
with complementary functions will be used instead. This would be preferable over the 1172 
currently often used FMT, where it is not well known what exact components are 1173 
transferred to the patient. One could imagine that these consortia could not only be 1174 
used to treat existing infections, but that they could also be administered 1175 
prophylactically in susceptible patient groups. In addition, more attention has recently 1176 
been given to several drugs that were previously not linked to gut health for their 1177 
potentially disturbing effect on gut microbiota and perhaps CR. In conclusion, we 1178 
reviewed many of the latest insights in the rapidly evolving fields of gut microbiota, 1179 
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colonization resistance and bacterial enteric infection. We are looking forward to the 1180 
coming years, where undoubtedly more knowledge will be gained on gut microbiota 1181 
and CR, ultimately leading to more microbiota-based therapies.  1182 
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FIGURE LEGENDS 1980 
FIG 1 Outline of gut microbiota-mediated colonization resistance mechanisms. Fiber 1981 
obtained from the diet is fermented by gut microbiota into short-chain fatty acids 1982 
(SCFAs). Bacteriocin producers produce bacteriocins capable of targeting a specific 1983 
pathogen. Primary bile acids can be converted by a very select group of gut 1984 
microbiota into secondary bile acids, which generally have antagonistic properties 1985 
against pathogens. Nutrient competition of native microbiota can limit access to 1986 
nutrients for a pathogen. Specific organisms can use SCFAs, bacteriocins and 1987 
primary bile acids to increase their virulence, as will be discussed in later sections.  1988 
 1989 
Fig 2 Vibrio cholerae uses a wide array of mechanisms to overcome CR. First, it 1990 
employs its acetate switch to use acetate for upregulating its own virulence. 1991 
Bacteriocin resistance remains to be mostly elucidated. To protect itself from 1992 
bacteriophages, V. cholerae produces outer membrane vesicles (OMVs) which act 1993 
as a decoy binding site for the attacking phages (see section: Bacterial defense 1994 
mechanisms against bacteriophages). Regulation of outer membrane porins is such 1995 
that they prevent entry of bile acids when they are encountered. By employing 1996 
specific mucin-degrading enzymes, V. cholerae releases sialic acid and 1997 
subsequently metabolizes it. 1998 
 1999 
Fig 3 Lytic and lysogenic bacteriophage infection cycle with bacterial defense 2000 
mechanisms. The first two steps (1 and 2) of infection are identical for the lytic and 2001 
lysogenic cycle, namely phage binding followed by DNA insertion and DNA 2002 
circularization. The lysogenic cycle then branches off by integrating its DNA into the 2003 
bacterial chromosome and becoming prophage, thereby ensuring its replication (3b). 2004 
82 
 
Only upon encountering induction factors will the prophage leave the bacterial 2005 
chromosome, after which it can enter the lytic cycle (4b and 5b). In the lytic cycle, 2006 
phage DNA and protein is replicated and subsequently assembled into full phages 2007 
(3a and 4a). The phages then lyse the bacterial cell, are released and can infect 2008 
other bacteria (5a). Bacteria possess multiple mechanisms to prevent killing by 2009 
bacteriophages, starting with blocking attachment. This can be achieved through 2010 
phase variation or production of OMVs. After phage DNA entry, CRISPR-Cas can 2011 
recognize this foreign DNA and degrade it. Phage DNA and protein replication can 2012 
be prevented by BREX and restriction modification systems, while full phage 2013 
assembly can be prevented by abortive infection.  2014 
 2015 



